Newcardio expert to present clinical validation data of Phase I and TQT studies on ECG

NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Dr. Sam George, NewCardio's Senior Consultant, will join a distinguished roster of speakers, moderators and panelists at the Cardiac Safety Research Consortium (CSRC) annual meeting in Maryland at the Marriot Bethesda, Pooks Hill location on October 29-30, 2009.

Dr. George, a cardiologist, was formerly Professor of Medicine and Pharmacology at Duke University Medical Center, and Director of Medical Affairs at CV Therapeutics, Inc. He is an Established Investigator of the American Heart Association.

The CSRC (www.cardiac-safety.org) is a broad-based collaboration of medical product safety experts from academia, industry, and the US Food and Drug Administration (FDA). It was formed in 2005 in response to the Critical Path Initiative, the FDA's premier effort to modernize the drug development process. The CSRC's primary goal is to facilitate development of new tools to improve cardiac safety assessment of medical products, especially tools to quantify arrhythmia (abnormal heart beat) risk of new drugs in development. With the FDA, the CSRC established a centralized ECG warehouse of ECGs obtained from drug clinical research studies.

Dr. George will make a presentation on the role of the CSRC's ECG warehouse from the point of view of a vendor. As part of this presentation, he is expected to present some of NewCardio's clinical validation data from several Phase I studies, including Thorough QT (TQT) studies based on 12-Lead ECG and full 24 hour Holter ECG data. In addition, he expects to discuss the true potential of the CSRC-FDA ECG Warehouse, and the steps the industry can take to achieve these goals. Following the presentation, Dr. George will participate in a discussion panel.

Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "NewCardio remains committed to the CSRC and we believe this organization has and will continue to help advance methods and solutions to improve cardiac safety in drug development. As an organization, we are excited to participate in this annual meeting and we endeavor to assist this organization in any way we can."

SOURCE NewCardio, Inc.